0
0
THIRUVANANTHAPURAM — A groundbreaking independent study released this week has debunked the long-standing myth that expensive branded medications are superior to their affordable generic counterparts. Conducted by the Mission for Ethics and Science in Health (MESH), the research revealed that generic drugs—including those distributed through India’s Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) and the Kerala Medical Services Corporation Ltd (KMSCL)—are therapeutically equivalent to branded versions that cost up to 14 times more. The findings suggest that patients suffering from chronic conditions like diabetes and hypertension could save tens of thousands of rupees annually without compromising their treatment outcomes.
Beyond the Brand: Quality is Not Linked to Price
For decades, both healthcare providers and patients have operated under the assumption that “cheaper means lower quality.” This skepticism has been a significant barrier to the adoption of generic medications in India and globally. However, the MESH study, which was notably crowd-funded to ensure institutional independence, provides rigorous laboratory evidence to the contrary.
Researchers analyzed 131 different medicines across 22 therapeutic categories, ranging from common antibiotics and acid reducers to essential treatments for chronic lifestyle diseases. The study utilized standardized pharmacological testing to measure the active pharmaceutical ingredients (API) and the dissolution rates of the drugs—key indicators of how well a medicine is absorbed into the bloodstream.
“The most important finding is that quality is not linked to price,” said Dr. Cyriac Abby Philips, a prominent clinician-scientist and President of MESH. “A tablet priced at ₹1 performed just as well in lab tests as the one that costs ₹10. This disproves the myth that cheaper means worse.”
The Cost of a Name
The price disparities highlighted in the report are staggering. For example, Metformin, the frontline treatment for Type 2 diabetes, is provided free of charge through KMSCL. At Jan Aushadhi stores, a strip of 10 tablets costs approximately ₹6.60. In contrast, branded versions of the same drug in private pharmacies can retail for ₹21.20 or more.
In categories like calcium supplements or proton-pump inhibitors (acid reducers), the price gap widens even further, with some patients paying 1,400% more simply for a brand name. For a patient managing multiple chronic conditions, switching to verified generics could result in savings of up to ₹66,000 per year.
Understanding Generics vs. Branded Drugs
To understand why these findings are significant, it is essential to distinguish between the types of medications available on the market:
-
Patented Branded Drugs: New drugs developed by a company that holds exclusive rights to sell them for a set period.
-
Branded Generics: Off-patent drugs sold by well-known pharmaceutical companies under a trade name (e.g., “Crocin” instead of just “Paracetamol”).
-
Unbranded Generics: Off-patent drugs sold by their chemical names, often through government outlets like Jan Aushadhi.
When a drug’s patent expires, other manufacturers can produce it. These companies do not have to repeat the expensive initial clinical trials, which is why they can sell the medicine at a lower cost. Regulatory bodies, such as the Central Drugs Standard Control Organisation (CDSCO) in India or the FDA in the United States, require these generics to have the same active ingredient, strength, and dosage form as the original.
Expert Perspectives: Bridging the Trust Gap
While the lab results are definitive, the “trust deficit” remains a hurdle. Dr. S. Mithun, a public health consultant not involved in the MESH study, notes that physician perception plays a massive role.
“Doctors often stick to branded generics because they trust the manufacturing consistency of large firms,” Dr. Mithun explained. “However, this study provides the objective data needed to reassure both doctors and patients that government-sourced generics are undergoing rigorous quality control. It’s a win for public health, especially in a country where out-of-pocket healthcare spending can push families into poverty.”
The study specifically validated drugs from the KMSCL and Jan Aushadhi networks, both of which have faced public scrutiny in the past regarding supply chain quality. By passing these independent tests, these institutions have gained a significant endorsement of their procurement and quality-assurance protocols.
Public Health Implications and Limitations
The implications for public health are profound. High drug prices are a primary cause of medication non-adherence, where patients skip doses or stop treatment because they cannot afford refills. By validating the efficacy of cheaper alternatives, the MESH study offers a roadmap for reducing the economic burden of disease.
Important Considerations
Despite the positive findings, experts urge a balanced approach:
-
Bioavailability: While lab tests (in-vitro) show the chemical similarity, some complex “biosimilar” drugs or sustained-release formulations may still require careful monitoring when switching brands.
-
Counterfeit Risks: The study highlights the quality of regulated generics. Patients should always purchase medications from licensed pharmacies or government-authorized outlets to avoid the risk of counterfeit products.
-
Physician Consultation: Patients should not switch medications for critical conditions—such as epilepsy or organ transplant rejection—without consulting their doctor, as these may have a “narrow therapeutic index.”
What This Means for You
For the average consumer, this research is an invitation to have an open conversation with their healthcare provider.
“Our study shows the overall quality of drugs is good,” Dr. Philips emphasized. “More importantly, it eliminates fear about generics. Patients who cannot afford branded medicines can safely opt for branded generics or free drugs provided by the government.”
Next time you receive a prescription, consider asking your doctor: “Is there a high-quality generic version of this medication available at a Jan Aushadhi store?” The answer could save you thousands without costing you your health.
References
-
Study Citation: Mission for Ethics and Science in Health (MESH). (2025). Comparative Analysis of Active Pharmaceutical Ingredients and Dissolution Profiles: Branded vs. Generic Medications in India. * Expert Source: Dr. Cyriac Abby Philips, President, MESH; Clinician-Scientist.
-
Additional Reporting: Based on findings first reported by Unnikrishnan S., The New Indian Express.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
